-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$3.671083.87% Upside
Marinus Pharmaceuticals, Inc. Frequently Asked Questions
-
What analysts cover Marinus Pharmaceuticals, Inc.?
Marinus Pharmaceuticals, Inc. has been rated by research analysts at Oppenheimer, Robert W. Baird, RBC Capital in the past 90 days.